Trial Profile
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms TOPAZ-I
- Sponsors AbbVie; AbbVie Germany
- 15 Jun 2021 This trial has been completed in Austria, according to European Clinical Trials Database.
- 01 Jun 2021 This trial has been completed in Greece, according to European Clinical Trials Database.
- 27 May 2021 Status changed from active, no longer recruiting to completed.